Summit Therapeutics Newsroom

Citi Downgrades Summit Therapeutics(SMMT.US) to Hold Rating, Raises Target Price to $23

Moomoo NewsSep 27 06:32 ET

Summit Therapeutics Downgraded to Neutral From Buy at Citi

TipRanksSep 27 05:40 ET

Summit Therapeutics Analyst Ratings

BenzingaSep 25 09:24 ET

Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $40

Moomoo NewsSep 25 07:31 ET

Stifel Nicolaus Sticks to Its Buy Rating for Summit Therapeutics (SMMT)

TipRanksSep 25 07:29 ET

H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45

Moomoo NewsSep 17 06:31 ET

Summit Therapeutics Analyst Ratings

BenzingaSep 16 06:52 ET

H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $45

Moomoo NewsSep 16 06:31 ET

Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $19

Moomoo NewsSep 9 07:33 ET

Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $25

Moomoo NewsSep 9 07:33 ET

Summit Therapeutics Analyst Ratings

BenzingaSep 9 06:38 ET

H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $30

Moomoo NewsSep 9 06:33 ET

H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsSep 3 06:33 ET

Summit Therapeutics' Ivonescimab Poised to Outperform KEYTRUDA: A Strong Buy Rating

TipRanksSep 3 06:27 ET

Summit Therapeutics Analyst Ratings

BenzingaAug 21 08:31 ET

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Arcadia Biosciences (RKDA)

TipRanksAug 21 06:35 ET

H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsAug 21 06:31 ET

H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsAug 15 06:36 ET

Summit Therapeutics Analyst Ratings

BenzingaAug 14 08:13 ET

H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $16

Moomoo NewsAug 14 06:34 ET